Folia Neuropathologica

Full text

2/2026 vol. 64
Original paper

Region-specific tau phosphorylation and microtubule pathology following α-synuclein exposure in the mouse brain: biochemical and ultrastructural evidence

Magdalena Gąssowska-Dobrowolska 1
,
Gabriela Olech-Kochańczyk 1
,
Magdalena Gewartowska 2
,
Lidia Babiec 3
,
Ewelina Bielska 1
,
Grzegorz Czapski 1
,
Anna Wilkaniec 1
,
Elżbieta Gawinek 1
,
Agata Adamczyk 1

  1. Department of Cellular Signalling, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland

  2. Electron Microscopy Research Unit, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland

  3. Center for Social and Affective Neuroscience, Linköping University, Linköping, Sweden

Folia Neuropathol 2026; 64 (2): 125-141

DOI: https://doi.org/10.5114/fn.2026.163699
Data publikacji online: 2026/07/24
Article file
Region Gassowska-Dobrowolska 02390.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Adamczyk A, Kacprzak M, Kaźmierczak A. Alpha-synuclein decreases arachidonic acid incorporation into rat striatal synaptoneurosomes. Folia Neuropathol 2007; 45: 230-235.
  2. Alonso A del C, Mederlyova A, Novak M, et al. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem 2004; 279: 34873-34881.
  3. Alonso AD, Cohen LS, Corbo C, et al. Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability. Front Cell Neurosci 2018; 12: 338.
  4. Babür E, Tan B, Delibaş S, et al. Depotentiation of long-term potentiation is associated with epitope-specific tau hyper-/hypophosphorylation in the hippocampus of adult rats. J Mol Neurosci 2019; 67: 193-203.
  5. Barbier P, Zejneli O, Martinho M, et al. Role of tau as a microtubule-associated protein: structural and functional aspects. Front Aging Neurosci 2019; 11: 204.
  6. Bielska E, Matuszewska M, Wójcik P, et al. Tau hypophosphorylation at Ser416 as the early molecular imprint of maternal immune activation: insights from female mice offspring. Int J Mol Sci 2025; 26: 10778.
  7. Bramblett GT, Goedert M, Jakes R, et al. Abnormal tau phosphorylation at Ser396 in Alzheimer’s disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993; 10: 1089-1099.
  8. Chakraborty R, Nonaka T, Hasegawa M, et al. Tunnelling nanotubes between neuronal and microglial cells allow bi-directional transfer of -Synuclein and mitochondria. Cell Death Dis 2023; 14: 329.
  9. Christensen KR, Combs B, Richards C, et al. Phosphomimetics at Ser199/Ser202/Thr205 in tau impairs axonal transport in rat hippocampal neurons. Mol Neurobiol 2023; 60: 3423-3438.
  10. Chu Y, Hirst WD, Federoff HJ, et al. Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease. Brain 2024; 147: 444-457.
  11. Chukwu JE, Congdon EE, Sigurdsson EM, et al. Structural characterization of monoclonal antibodies targeting C-terminal Ser404 region of phosphorylated tau protein. MAbs 2019; 11: 477-488.
  12. Cisbani G, Maxan A, Kordower JH, et al. Presence of tau pathology within foetal neural allografts in patients with Huntington’s and Parkinson’s disease. Brain 2017; 140: 2982-2992.
  13. Conde C, Cáceres A. Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 2009; 10: 319-332.
  14. Danzer KM, Kranich LR, Ruf WP, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener 2012; 7: 42.
  15. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009; 106: 13010-13015.
  16. Domert J, Sackmann C, Severinsson E, et al. Aggregated alpha-synuclein transfer efficiently between cultured human neuron-like cells and localize to lysosomes. PLoS One 2016; 11: e0168700.
  17. Duka T, Duka V, Joyce JN, et al. Alpha-synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson’s disease models. FASEB J 2009; 23: 2820-2830.
  18. Duka T, Rusnak M, Drolet RE, et al. Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J 2006; 20: 2302-2312.
  19. Evans DB, Rank KB, Bhattacharya K, et al. Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau’s ability to promote microtubule assembly. J Biol Chem 2000; 275: 24977-24983.
  20. Fan X, Okada K, Lin H, et al. A pathological phosphorylation pattern enhances tau cooperativity on microtubules and facilitates tau filament assembly. Res Sq 2025; rs.3.rs-6247226/v1.
  21. Faul F, Erdfelder E, Lang AG, et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175-191.
  22. Fischer AL, Schmitz M, Thom T, et al. Alpha-synuclein demonstrates varying binding affinities with different tau isoforms. J Neurochem 2025; 169: e70053.
  23. Forman MS, Schmidt ML, Kasturi S, et al. Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. Am J Pathol 2002; 160: 1725-1731.
  24. Franzmeier N, Roemer-Cassiano SN, Bernhardt AM, et al. Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease. Mol Neurodegener 2025; 20: 31.
  25. Frasier M, Walzer M, McCarthy L, et al. Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol 2005; 192: 274-287.
  26. Galloway PG, Mulvihill P, Perry G. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol 1992; 140: 809-822.
  27. Gąssowska-Dobrowolska M, Czapski GA, Cieślik M, et al. Microtubule cytoskeletal network alterations in a transgenic model of tuberous sclerosis complex: relevance to autism spectrum disorders. Int J Mol Sci 2023; 24: 7303.
  28. Haggerty T, Credle J, Rodriguez O, et al. Hyperphosphorylated Tau in an -synuclein-overexpressing transgenic model of Parkinson’s disease. Eur J Neurosci 2011; 33: 1598-1610.
  29. Hansen C, Angot E, Bergström AL, et al. -Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121: 715-725.
  30. Ikura Y, Kudo T, Tanaka T, et al. Levels of tau phosphorylation at different sites in Alzheimer disease brain. Neuroreport 1998; 9: 2375-2379.
  31. Iqbal K, Alonso A del C, Chen S, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005; 1739: 198-210.
  32. Iqbal K, Liu F, Gong CX, et al. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2010; 7: 656-664.
  33. Itoh N, Arai H, Urakami K, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease. Ann Neurol 2001; 50: 150-156.
  34. Jameson L, Frey T, Zeeberg B, et al. Inhibition of microtubule assembly by phosphorylation of microtubule-associated proteins. Biochemistry 1980; 19: 2472-2479.
  35. Jin M, Wang S, Gao X, et al. Pathological and physiological functional cross-talks of -synuclein and tau in the central nervous system. Neural Regen Res 2024; 19: 855-862.
  36. Johnson GVW, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 2004; 117 (Pt 24): 5721-5729.
  37. Kawakami F, Suzuki M, Shimada N, et al. Stimulatory effect of -synuclein on the tau-phosphorylation by GSK-3. FEBS J 2011; 278: 4895-4904.
  38. Khandelwal PJ, Dumanis SB, Feng LR, et al. Parkinson-related parkin reduces -Synuclein phosphorylation in a gene transfer model. Mol Neurodegener 2010; 5: 47.
  39. Kotzbauer PT, Giasson BI, Kravitz AV, et al. Fibrillization of alpha-synuclein and tau in familial Parkinson’s disease caused by the A53T alpha-synuclein mutation. Exp Neurol 2004; 187: 279-288.
  40. Lei P, Ayton S, Finkelstein DI, et al. Tau protein: relevance to Parkinson’s disease. Int J Biochem Cell Biol 2010; 42: 1775-1778.
  41. Li T, Paudel HK. Glycogen synthase kinase 3beta phosphorylates Alzheimer’s disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry 2006; 45: 3125-3133.
  42. Lindwall G, Cole RD. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 1984; 259: 5301-5305.
  43. Loria F, Vargas JY, Bousset L, et al. -Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading. Acta Neuropathol 2017; 134: 789-808.
  44. Luk KC, Kehm V, Carroll J, et al. Pathological -synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338: 949-953.
  45. Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological -synuclein initiates a rapidly progressive neurodegenerative -synucleinopathy in mice. J Exp Med 2012; 209: 975-986.
  46. Man VH, He X, Gao J, et al. Phosphorylation of Tau R2 repeat destabilizes its binding to microtubules: a molecular dynamics simulation study. ACS Chem Neurosci 2023; 14: 458-467.
  47. Mietelska-Porowska A, Wasik U, Goras M, et al. Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci 2014; 15: 4671-4713.
  48. Mondragón-Rodríguez S, Perry G, Luna-Muñoz J, et al. Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer’s disease and Down syndrome. Neuropathol Appl Neurobiol 2014; 40: 121-135.
  49. Muntané G, Dalfó E, Martinez A, et al. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer’s disease, and in Parkinson’s disease and related alpha-synucleinopathies. Neuroscience 2008; 152: 913-923.
  50. Nadel CM, Pokhrel S, Wucherer K, et al. Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP. Nat Commun 2024; 15: 7972.
  51. Neddens J, Temmel M, Flunkert S, et al. Phosphorylation of different tau sites during progression of Alzheimer’s disease. Acta Neuropathol Commun 2018; 6: 52.
  52. Otvos L, Feiner L, Lang E, et al. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 1994; 39: 669-673.
  53. Pacheco CR, Morales CN, Ramírez AE, et al. Extracellular -synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane. J Neurochem 2015; 132: 731-741.
  54. Padilla-Godínez FJ, Vázquez-García ER, Trujillo-Villagrán MI, et al. -synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies. Front Neurosci 2025; 19: 1570553.
  55. Porzig R, Singer D, Hoffmann R. Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem Biophys Res Commun 2007; 358: 644-649.
  56. Reyes JF, Olsson TT, Lamberts JT, et al. A cell culture model for monitoring -synuclein cell-to-cell transfer. Neurobiol Dis 2015; 77: 266-275.
  57. Sengupta U, Kayed R. Amyloid , Tau, and -Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog Neurobiol 2022; 214: 102270.
  58. Sferra A, Nicita F, Bertini E. Microtubule dysfunction: a common feature of neurodegenerative diseases. Int J Mol Sci 2020; 21: 7354.
  59. Shahpasand K, Uemura I, Saito T, et al. Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer’s disease. J Neurosci 2012; 32: 2430-2441.
  60. Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron 2014; 82: 756-771.
  61. Tai HC, Serrano-Pozo A, Hashimoto T, et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 2012; 181: 1426-1435.
  62. Torres AK, Jara C, Olesen MA, et al. Pathologically phosphorylated tau at S396/404 (PHF-1) is accumulated inside of hippocampal synaptic mitochondria of aged Wild-type mice. Sci Rep 2021; 11: 4448.
  63. Tu H, Zhang ZW, Qiu L, et al. Increased expression of pathological markers in Parkinson’s disease dementia post-mortem brains compared to dementia with Lewy bodies. BMC Neurosci 2022; 23: 3.
  64. Vacchi E, Kaelin-Lang A, Melli G. Tau and alpha synuclein synergistic effect in neurodegenerative diseases: when the periphery is the core. Int J Mol Sci 2020; 21: 5030.
  65. Vermilyea SC, Christensen A, Meints J, et al. Loss of tau expression attenuates neurodegeneration associated with -synucleinopathy. Transl Neurodegener 2022; 11: 34.
  66. Volpicelli-Daley LA, Luk KC, Lee VMY. Addition of exogenous -synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous -synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc 2014; 9: 2135-2146.
  67. Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci 2016; 17: 5-21.
  68. Wilkaniec A, Czapski GA, Cieślik M, et al. Soluble -synuclein oligomers drive transient corticostriatal pathology and delayed nigral vulnerability in a mouse model of early -synucleinopathy. Acta Neuropathol Commun 2026, doi: 10.1186/s40478-026-02340-9.
  69. Wills J, Credle J, Haggerty T, et al. Tauopathic changes in the striatum of A53T -synuclein mutant mouse model of Parkinson’s disease. PLoS One 2011; 6: e17953.
  70. Wills J, Jones J, Haggerty T, et al. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia. Exp Neurol 2010; 225: 210-218.
  71. Wu M, Zhang M, Yin X, et al. The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases. Transl Neurodegener 2021; 10: 45.
  72. Xia Y, Zhang G, Han C, et al. Microglia as modulators of exosomal alpha-synuclein transmission. Cell Death Dis 2019; 10: 174.
  73. Yamamoto H, Hiragami Y, Murayama M, et al. Phosphorylation of tau at serine 416 by Ca2+/calmodulin-dependent protein kinase II in neuronal soma in brain. J Neurochem 2005; 94: 1438-1447.
  74. Yang SD, Song JS, Yu JS, et al. Protein kinase FA/GSK-3 phosphorylates tau on Ser235-Pro and Ser404-Pro that are abnormally phosphorylated in Alzheimer’s disease brain. J Neurochem 1993; 61: 1742-1747.
  75. Zemlan FP, Dean GE. Monoclonal antibody PHF-9 recognizes phosphorylated serine 404 of tau protein and labels paired helical filaments. J Neurosci Res 1996; 46: 90-97.
  76. Zhang X, Wang J, Zhang Z, et al. Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies. Transl Neurodegener 2024; 13: 40.
Copyright: © 2026 Mossakowski Medical Research Centre Polish Academy of Sciences and the Polish Association of Neuropathologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications